354P - Survival trends of primary testicular diffuse large B-cell lymphoma: A population-based study

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Lymphomas
Presenter Mohammed Mousa
Citation Annals of Oncology (2016) 27 (suppl_9): ix104-ix111. 10.1093/annonc/mdw586
Authors M. Mousa, A. Meshref
  • Faculty Of Medicine, Suez Canal University, 00202 - Ismailia/EG

Abstract

Background

Primary Testicular lymphoma is considered a rare disease with a limited data on its survival trends and outcomes of treatment. In our study, we aimed at evaluation of 5-year relative survival rates of these patients in a large sample using the Surveillance, Epidemiology, and End Results (SEER) Registry of the United States.

Methods

Kaplan-Meir method was used to analyze the 5-year relative survival rates of 1074 primary testicular diffuse large B-Cell lymphoma cases using SEER*Stat Program. Relative survival rates were calculated using Z-test among groups of patients categorized by year of diagnosis, race, age groups and laterality.

Results

We found a statistically significant increase in the relative survival rates in the group of patients diagnosed in and after the year of 2000 which is the year of introduction of rituximab to the treatment protocols (66.8% ± 2.6%) in comparison to patients diagnosed before the year of 2000 (54.1% ± 3.3%, P = 0.005). When the study population was categorized according to age at diagnosis (18-59, 60-69, 70-79 and older than 80 years old) the 5-year relative survival rates were 96.5%, 62.7% 59.9% and 46.1% respectively (P 

Conclusions

The introduction of rituximab to the treatment protocols, younger age at the time of diagnosis and unilateral tumors seems to have better relative survival rates in such cases. Such results can be used in reforming the disease surveillance and prognostic counseling programs in a better manner.

Clinical trial indentification

Legal entity responsible for the study

The Surveillance, Epidemiology, and End Results (SEER) Program of the American National Cancer Institute

Funding

Suez Canal University

Disclosure

All authors have declared no conflicts of interest.